Getting a GLP-1 medication covered by insurance almost always follows the same sequence: verify the drug is on your plan’s formulary, make sure your doctor prescribes it under the strongest qualifying diagnosis you have, submit complete clinical documentation through prior authorization, satisfy any step therapy requirement (or request an exception), and appeal if the answer comes back no. Ozempic, Wegovy, Mounjaro, and Zepbound all follow this path, but the diagnosis on your prescription changes the odds dramatically. Insurers treat diabetes, cardiovascular risk, sleep apnea, liver disease, and plain weight management as separate coverage questions with separate approval thresholds.
Start With Your Plan’s Formulary
Before your doctor writes anything, find out what your plan actually covers. The formulary is the list of covered medications, and every plan publishes one on the insurer’s website or by phone using the number on your card. You want two pieces of information: whether the specific GLP-1 is on the list, and which tier it sits on. GLP-1s frequently land on the non-preferred brand or specialty tier, which means coinsurance of 25% to 50% rather than a flat copay.
Plan type matters. Employer-sponsored plans negotiate their own formularies, so the same insurer might cover Ozempic on one employer’s plan and exclude it on another. Marketplace plans have their own rules. Pull your Summary of Benefits and Coverage document and read the exclusions carefully. Some plans exclude all weight-loss medications outright. Others cover GLP-1s for diabetes but not for weight management. Knowing exactly what your plan says before your doctor submits anything can save weeks.
If the drug isn’t on your formulary at all, you’re looking at either a formulary exception request or switching to a covered alternative in the same class.
Get the Diagnosis Right
The FDA-approved indication on your prescription is the single biggest factor in whether the drug gets approved. Recent FDA actions have opened several pathways beyond the original diabetes and weight-loss uses, and some are much easier to get covered than others.
- Type 2 diabetes is the most straightforward. Most commercial plans and Medicare Part D cover GLP-1s prescribed for diabetes, though prior authorization and step therapy are still common.
- Cardiovascular risk reduction became a coverage pathway when the FDA approved Wegovy in March 2024 to reduce the risk of heart attack, stroke, and cardiovascular death in adults with established cardiovascular disease and either obesity or overweight.1U.S. Food and Drug Administration. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults With Obesity or Overweight
- Obstructive sleep apnea is another route since the FDA approved Zepbound in December 2024 for moderate-to-severe OSA in adults with obesity.2U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea
- MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced liver scarring became a Wegovy indication in August 2025. Coverage typically requires a specialist prescription and documented fibrosis staging.3U.S. Food and Drug Administration. FDA Approves Treatment for Serious Liver Disease Known as MASH
- Weight management alone is the hardest to get covered. Plans that do cover it generally require a BMI of 30 or higher, or 27 with an obesity-related condition. Many plans exclude weight-loss drugs entirely.
The practical move: if you have a qualifying condition beyond weight loss, make sure your doctor prescribes under that indication. A prescription written for cardiovascular risk reduction in a patient with documented heart disease faces a very different review than the same drug written for weight management.
Build the Medical Documentation
Insurers don’t take a doctor’s word for it. They want records that prove you meet specific clinical criteria, and incomplete documentation is the most common reason for delays and denials.
For type 2 diabetes, expect to provide recent A1C results, blood sugar logs, and records of what you’ve already tried. The American Diabetes Association’s Standards of Care recommends an A1C target below 7% for most adults with type 2 diabetes, and insurers frequently use that benchmark when evaluating whether current treatment is adequate.4American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes 2025 An A1C that stays above target on other medications strengthens the case considerably.
For weight management, your doctor should document BMI history over time, previous weight-loss efforts (diet, exercise, prior medications), and any obesity-related conditions. For cardiovascular or sleep apnea indications, expect relevant test results like echocardiograms or sleep studies to be part of the submission.
Ask your doctor to include a letter of medical necessity that speaks directly to the insurer’s clinical criteria rather than making a general case. Letters that address the criteria point by point carry real weight with reviewers.
Prior Authorization: How It Works
Nearly every plan requires prior authorization before covering a GLP-1. Your doctor’s office submits a formal request with the supporting documentation, and the insurer’s clinical team reviews it before the pharmacy can fill the prescription.
Federal rules set the outer boundaries. As of January 2026, standard prior authorization decisions must come within 7 calendar days for plans subject to federal interoperability rules, down from 14 days. Expedited reviews for urgent situations must be completed within 72 hours. Many decisions come back faster in practice, especially when the office uses electronic prior authorization systems instead of fax.
Common reasons requests stall: missing lab results, incomplete forms, or documentation that doesn’t clearly address the insurer’s criteria. Some insurers publish their clinical criteria online. If yours does, use it as a checklist before submission. Confirm with your doctor’s office that they’ve included everything the form requires.
An approved authorization is typically valid for six months to a year, after which a renewal request is needed. Some plans require you to show continued clinical benefit at renewal, such as maintaining A1C improvements or achieving at least 5% body weight loss within the first year. Miss the renewal deadline and you may restart the whole process, so mark the expiration date.
Step Therapy and How to Skip It
Many plans won’t approve a GLP-1 until you’ve tried and failed on cheaper alternatives. For diabetes, that usually means documented use of metformin and possibly a sulfonylurea. For weight management, plans may require evidence that diet, exercise, or other weight-loss medications didn’t produce adequate results. One or two prior medications is typical.
What you document matters more than what you filled. Your doctor needs to record what happened on the alternative: did your A1C stay above target, did you have side effects like severe nausea or hypoglycemia, did you lose insufficient weight? Specific clinical outcomes carry the request.
Requesting a Step Therapy Exception
You don’t always have to work through medications your doctor already knows won’t help. Most plans allow exceptions when there’s a clinical reason to skip step therapy: a documented contraindication, a history of adverse reactions, or medical evidence that the required drug is likely to be ineffective or harmful in your specific case.
Specificity wins these. “Patient cannot tolerate metformin” is weaker than “Patient developed lactic acidosis symptoms on metformin 500mg twice daily, discontinued after 14 days per clinical notes dated [date].”
What to Do If You’re Denied
Denials happen even when you’ve done everything right. The denial letter should state the insurer’s reasoning, whether that’s insufficient documentation, unmet clinical criteria, or incomplete step therapy. If the letter is vague, call and ask for a specific explanation. You can’t effectively appeal what you don’t understand.
Internal Appeal
The first step is a formal internal appeal, where the insurer reconsiders based on additional information. Your doctor should submit updated records, a letter addressing the specific reason for denial, and any new test results that strengthen the case. Most plans allow 180 days from the denial date to file, though speed matters when you need the medication.
External Review
If the internal appeal fails, federal law gives you the right to an external review by an independent review organization that has no ties to your insurer.5U.S. Department of Health and Human Services. Internal Claims and Appeals and the External Review Process Overview The independent reviewer must issue a decision within 45 days for standard cases, or within 72 hours for expedited cases involving urgent medical situations.6eCFR. 45 CFR 147.136 – Internal Claims and Appeals and External Review Processes The decision is binding on the insurer. External review overturns denials more often than most patients expect, especially when the medical documentation is strong.
Check whether your employer offers benefits advocacy services. Some larger employers contract with firms that help employees navigate insurance disputes, and these advocates know how to frame appeals.
Medicare Coverage Works Differently
Medicare Part D covers GLP-1 medications when prescribed for type 2 diabetes, cardiovascular risk reduction, or obstructive sleep apnea. Federal law has historically prohibited Part D from covering drugs used solely for weight loss, an exclusion that traces to the Social Security Act.7Social Security Administration. Social Security Act 1860D-2 CMS has proposed reinterpreting the exclusion to permit coverage of anti-obesity medications for people with obesity, but that proposal has not been finalized as of mid-2026.8Centers for Medicare and Medicaid Services. Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program Separate legislation called the Treat and Reduce Obesity Act has been introduced but remains in committee.9U.S. Congress. H.R.4231 – Treat and Reduce Obesity Act of 2025 Coverage for weight loss alone is not available through the standard Part D benefit.10U.S. Department of Health and Human Services. Medicare Coverage of Anti-Obesity Medications
If your doctor can prescribe the GLP-1 under a covered indication like diabetes or cardiovascular risk reduction, Part D handles it through the normal prior authorization process.
The Medicare GLP-1 Bridge
For the second half of 2026, CMS is running a temporary demonstration called the Medicare GLP-1 Bridge that covers GLP-1 medications approved for weight reduction in eligible Part D enrollees.11Centers for Medicare and Medicaid Services. Medicare GLP-1 Bridge The program runs from July 1 through December 31, 2026 and operates outside the standard Part D benefit. Eligibility is based on BMI thresholds and clinical criteria, and applicable utilization management must be completed. If you’re a Medicare beneficiary interested in weight-related GLP-1 coverage, check the CMS Bridge page for current enrollment details.
The Out-of-Pocket Cap and Payment Plan
Part D has an annual out-of-pocket spending cap set at $2,100 for 2026.12Centers for Medicare and Medicaid Services. Final CY 2026 Part D Redesign Program Instructions Once you hit it, you pay nothing more for covered prescriptions for the rest of the year. Medicare also offers a Prescription Payment Plan that lets you spread out-of-pocket drug costs across the calendar year in monthly installments rather than paying the full amount at the pharmacy.13Medicare. What’s the Medicare Prescription Payment Plan? Fill an expensive GLP-1 prescription in January and you can spread that cost over twelve months.
Lowering Costs When Coverage Falls Short
If your plan denies coverage or your share is still too high, several options can bring costs down.
Manufacturer Savings Programs
Novo Nordisk’s Patient Assistance Program provides Ozempic at no cost to qualifying patients who are uninsured or on Medicare, with income at or below 200% of the federal poverty level for uninsured patients.14NovoCare. Novo Nordisk Patient Assistance Program (PAP) Eli Lilly’s Mounjaro Savings Card reduces the copay to as little as $25 per month for patients with commercial insurance that covers the drug, or $499 per month for commercially insured patients whose plan doesn’t cover it.15Eli Lilly. Savings and Resources – Mounjaro Manufacturer programs typically exclude patients enrolled in government programs like Medicaid, Medicare, or TRICARE.
HSA and FSA Dollars
Prescription drugs are eligible expenses for health savings accounts and flexible spending accounts.16FSAFEDS. Eligible Health Care FSA (HC FSA) Expenses Paying with pre-tax dollars is effectively a discount equal to your marginal tax rate. For someone in the 22% bracket, a $200 monthly copay paid through an HSA or FSA saves roughly $44 per month in taxes.
A Note on Compounded GLP-1s
Compounding pharmacies offer semaglutide and tirzepatide at substantially lower prices. The FDA has signaled that national GLP-1 supply is stabilizing and has stated its intent to take enforcement action against compounders making non-FDA-approved GLP-1 products.17U.S. Food and Drug Administration. FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs Compounded versions are not FDA-approved, may vary in potency and purity, and cannot legally be marketed as equivalent to brand-name products. Exhaust manufacturer assistance and appeals before turning to compounded alternatives.
Keeping Coverage When You Change Plans
Changing jobs, aging into Medicare, or switching marketplace plans mid-treatment puts your prior authorization at risk. A new plan has no obligation to honor the old plan’s approval, and you may need to restart the entire process.
Some states require new plans to honor existing prior authorizations for a transitional period, commonly 90 days, while utilization management is completed under the new plan. Even without such a law, many insurers offer a grace period for patients already stabilized on a medication. Call your new plan before your coverage switch date, ask about transition-of-care policies for specialty medications, and get whatever you’re told in writing.
If you’re facing a gap, ask your current doctor to submit prior authorization to the new plan before old coverage ends. For Medicare beneficiaries switching Part D plans during open enrollment, prior authorizations from the old plan expire on December 31 of the current year.
Medicaid coverage of GLP-1s varies significantly by state. Most state Medicaid programs cover them for type 2 diabetes, but coverage for weight management is far less consistent, and some states have scaled back that coverage due to cost. Check with your state’s Medicaid program directly, since formularies and prior authorization requirements change frequently.